217 related articles for article (PubMed ID: 29785551)
21. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
Yamamoto H; Uryu H; Segawa Y; Tsuneyoshi M
Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
[TBL] [Abstract][Full Text] [Related]
22. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
23. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
Nakaguro M; Tada Y; Faquin WC; Sadow PM; Wirth LJ; Nagao T
Cancer Cytopathol; 2020 Oct; 128(10):693-703. PubMed ID: 32421944
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML
Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
26. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis.
Moriki T; Ueta S; Takahashi T; Mitani M; Ichien M
Cancer; 2001 Oct; 93(5):344-50. PubMed ID: 11668470
[TBL] [Abstract][Full Text] [Related]
27. Management and outcome of salivary duct carcinoma in major salivary glands.
Salovaara E; Hakala O; Bäck L; Koivunen P; Saarilahti K; Passador-Santos F; Leivo I; Mäkitie AA
Eur Arch Otorhinolaryngol; 2013 Jan; 270(1):281-5. PubMed ID: 22437251
[TBL] [Abstract][Full Text] [Related]
28. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
[TBL] [Abstract][Full Text] [Related]
30. Salivary duct carcinoma: Treatment, outcomes, and patterns of failure.
Johnston ML; Huang SH; Waldron JN; Atenafu EG; Chan K; Cummings BJ; Gilbert RW; Goldstein D; Gullane PJ; Irish JC; Perez-Ordonez B; Weinreb I; Bayley A; Cho J; Dawson LA; Hope A; Ringash J; Witterick IJ; O'Sullivan B; Kim J
Head Neck; 2016 Apr; 38 Suppl 1():E820-6. PubMed ID: 25916947
[TBL] [Abstract][Full Text] [Related]
31. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines.
Sood S; McGurk M; Vaz F
J Laryngol Otol; 2016 May; 130(S2):S142-S149. PubMed ID: 27841127
[TBL] [Abstract][Full Text] [Related]
32. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
[TBL] [Abstract][Full Text] [Related]
33. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
Murata K; Kawahara A; Ono T; Takase Y; Abe H; Naito Y; Akiba J
Diagn Cytopathol; 2018 May; 46(5):429-433. PubMed ID: 29205961
[TBL] [Abstract][Full Text] [Related]
34. Management and outcome of patients with malignant salivary gland tumors.
Bell RB; Dierks EJ; Homer L; Potter BE
J Oral Maxillofac Surg; 2005 Jul; 63(7):917-28. PubMed ID: 16003616
[TBL] [Abstract][Full Text] [Related]
35. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
36. [Salivary duct carcinoma--a clinicopathological analysis of five cases].
Bień S; Sygut J; Kopczyński J; Postuła S; Ziółkowska M
Otolaryngol Pol; 2007; 61(1):33-8. PubMed ID: 17605416
[TBL] [Abstract][Full Text] [Related]
37. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
Fan CY; Wang J; Barnes EL
Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
[TBL] [Abstract][Full Text] [Related]
38. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological analysis of 40 cases of salivary duct carcinoma].
Lin N; Cai JH; Xu MJ; Kang P; Cheng ZF; He W
Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Jun; 54(6):416-419. PubMed ID: 31177683
[No Abstract] [Full Text] [Related]
40. The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center.
Mayer M; Wolber P; Prinz J; Jansen L; Esser J; Shabli S; Quaas A; Klußmann JP; Sharma SJ; Nachtsheim L; Arolt C
Eur Arch Otorhinolaryngol; 2024 Apr; ():. PubMed ID: 38587651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
